ORIC Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

ORIC Pharmaceuticals'in kazancının yıllık 6.9% oranında azalması, yıllık gelirinin ise yıllık 69.6% oranında artması beklenmektedir. EPS'nin yılda 4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -49.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

-6.9%

Kazanç büyüme oranı

4.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	69.6%
Gelecekteki özkaynak getirisi	-49.6%
Analist kapsamı	Good
Son güncelleme	20 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:4TZ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	11	-185	-150	-164	9
12/31/2025	N/A	-161	-123	-127	11
12/31/2024	N/A	-127	-97	-89	11
9/30/2024	N/A	-120	-110	-109	N/A
6/30/2024	N/A	-111	-100	-100	N/A
3/31/2024	N/A	-102	-96	-95	N/A
12/31/2023	N/A	-101	-87	-86	N/A
9/30/2023	N/A	-93	-78	-77	N/A
6/30/2023	N/A	-93	-78	-76	N/A
3/31/2023	N/A	-90	-75	-73	N/A
12/31/2022	N/A	-89	-77	-75	N/A
9/30/2022	N/A	-91	-78	-76	N/A
6/30/2022	N/A	-85	-71	-69	N/A
3/31/2022	N/A	-85	-69	-67	N/A
12/31/2021	N/A	-79	-60	-60	N/A
9/30/2021	N/A	-84	-62	-61	N/A
6/30/2021	N/A	-91	-59	-59	N/A
3/31/2021	N/A	-81	-53	-52	N/A
12/31/2020	N/A	-74	-46	-45	N/A
9/30/2020	N/A	-54	-35	-35	N/A
6/30/2020	N/A	-35	-31	-30	N/A
3/31/2020	N/A	-30	-27	-26	N/A
12/31/2019	N/A	-27	-24	-24	N/A
12/31/2018	N/A	-21	-21	-21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4TZ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 4TZ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 4TZ önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 4TZ gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: 4TZ gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4TZ 3 yıl içinde kârsız olması bekleniyor.

ORIC Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

President recently bought €1.2m worth of stock

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

ORIC Pharmaceuticals, Inc. Provides Corporate Update

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

New 90-day high: €30.20

New 90-day high: €22.80

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: €17.00

ORIC Pharmaceuticals, Inc. announced that it expects to receive funding from a group of investors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin